Scarica l'app Stockscreener
11.23
1.54%
0.21
Precedente Chiudi:
$11.02
Aprire:
$11.09
Volume 24 ore:
184.59K
Relative Volume:
0.32
Capitalizzazione di mercato:
$239.54M
Reddito:
$66.59M
Utile/perdita netta:
$-104.93M
Rapporto P/E:
-2.2687
EPS:
-4.95
Flusso di cassa netto:
$-96.48M
1 W Prestazione:
-1.41%
1M Prestazione:
+35.14%
6M Prestazione:
+138.59%
1 anno Prestazione:
+1.36%
Intervallo 1D:
$10.96
$11.33
Intervallo di 1 settimana:
$10.81
$11.82
Portata 52W:
$4.09
$15.34
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Nome
Enanta Pharmaceuticals Inc
Settore
Industria
Telefono
617 607 0800
Indirizzo
4 KINGSBURY AVENUE, WATERTOWN, MA
Confronta ENTA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
11.21 | 317.96M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.81 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.68 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.20 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
809.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.45 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-01 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-07-28 | Ripresa | H.C. Wainwright | Buy |
| 2023-08-09 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-08-08 | Downgrade | Jefferies | Buy → Hold |
| 2022-12-09 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-06-01 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-09-09 | Iniziato | SVB Leerink | Mkt Perform |
| 2021-01-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-11-24 | Iniziato | Evercore ISI | Underperform |
| 2020-08-28 | Ripresa | ROTH Capital | Buy |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-07-27 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-05-24 | Iniziato | Wolfe Research | Outperform |
| 2019-04-23 | Aggiornamento | Berenberg | Hold → Buy |
| 2018-12-13 | Iniziato | Berenberg | Hold |
| 2018-06-06 | Iniziato | ROTH Capital | Buy |
| 2018-02-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-07-11 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Reiterato | Barclays | Underweight |
| 2015-10-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2015-10-23 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
Mostra tutto
Enanta Pharmaceuticals Inc Borsa (ENTA) Ultime notizie
How Enanta Pharmaceuticals Inc. stock performs in rising dollar environmentTrade Risk Report & Low Drawdown Trading Techniques - newser.com
Why Enanta Pharmaceuticals Inc. stock is rated strong buyJuly 2025 Update & Fast Entry High Yield Tips - newser.com
How Enanta Pharmaceuticals Inc. stock compares to growth peers2025 Key Lessons & Detailed Earnings Play Alerts - newser.com
Enanta pharmaceuticals prices $65M common stock offering - MSN
Chart based analysis of Enanta Pharmaceuticals Inc. trendsJuly 2025 Intraday Action & Daily Profit Focused Screening - newser.com
Why Enanta Pharmaceuticals Inc. stock is seen as undervalued2025 Institutional Moves & Fast Momentum Stock Entry Tips - newser.com
Published on: 2025-10-10 06:04:18 - newser.com
Using economic indicators to assess Enanta Pharmaceuticals Inc. potentialJuly 2025 Technicals & Technical Pattern Alert System - newser.com
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
What high frequency data says about Enanta Pharmaceuticals Inc.Quarterly Market Review & Fast Gain Swing Alerts - newser.com
Enanta Pharmaceuticals' (ENTA) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Does Enanta Pharmaceuticals Inc. show high probability of rebound2025 Growth vs Value & Fast Exit and Entry Strategy Plans - newser.com
Is Enanta Pharmaceuticals Inc a good long term investmentGap Fill Strategies & Individual Stock Tracking Service - earlytimes.in
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development fo - PharmiWeb.com
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek 2025 - Business Wire
Backtesting results for Enanta Pharmaceuticals Inc. trading strategies2025 Key Lessons & Risk Controlled Stock Alerts - newser.com
What’s next for Enanta Pharmaceuticals Inc. stock priceJuly 2025 Closing Moves & Stepwise Entry and Exit Trade Signals - newser.com
Quantitative breakdown of Enanta Pharmaceuticals Inc. recent moveWeekly Stock Report & Short-Term High Return Ideas - newser.com
Will Enanta Pharmaceuticals Inc. stock benefit from AI adoptionAnalyst Downgrade & Expert Curated Trade Setups - newser.com
Is Enanta Pharmaceuticals Inc. (9EP) stock a buy during volatile markets2025 Market Sentiment & Fast Entry High Yield Tips - newser.com
What Fibonacci levels say about Enanta Pharmaceuticals Inc. reboundJuly 2025 Momentum & Consistent Profit Alerts - newser.com
Is Enanta Pharmaceuticals Inc. (9EP) stock bottoming after sell offJobs Report & Daily Momentum Trading Reports - newser.com
Why Enanta Pharmaceuticals Inc. (9EP) stock gets analyst attention2025 Market Sentiment & Reliable Intraday Trade Alerts - newser.com
What’s the recovery path for long term holders of Enanta Pharmaceuticals Inc.Market Sentiment Report & Safe Swing Trade Setups - newser.com
Real time alert setup for Enanta Pharmaceuticals Inc. performanceJuly 2025 Opening Moves & Free Weekly Chart Analysis and Trade Guides - newser.com
What analysts say about Enanta Pharmaceuticals Inc 9EP stockRisk Management Strategies & Minimal Risk High Reward - earlytimes.in
Foley Hoag Advises Enanta Pharmaceuticals on $74.8 Million Upsized Public Offering - Foley Hoag
Enanta upgraded to buy at Jefferies on promise of RSV antiviral zalicapavir - MSN
Enanta Pharmaceuticals (ENTA) Is Up 33.3% After Positive Phase 2b RSV Results Propel Zelicapavir Forward - Sahm
Is Enanta Pharmaceuticals Inc. stock entering bullish territory2025 Geopolitical Influence & Smart Money Movement Tracker - newser.com
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full - PharmiWeb.com
Enanta Pharmaceuticals raises $74.75 million in public offering By Investing.com - Investing.com Canada
Enanta Pharmaceuticals raises $74.75 million in public offering - Investing.com
Enanta Pharmaceuticals announces closing of upsized public offering of common stock - MarketScreener
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - FinancialContent
Enanta Pharmaceuticals falls on public offering of common stock - MSN
FY2027 Earnings Estimate for ENTA Issued By Leerink Partnrs - MarketBeat
Enanta Pharmaceuticals Announces Public Stock Offering - TipRanks
Enanta Pharmaceuticals Inc Azioni (ENTA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Enanta Pharmaceuticals Inc Azioni (ENTA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kieffer Tara Lynn | Chief Product Strategy Officer |
Dec 06 '24 |
Sale |
8.06 |
2,283 |
18,401 |
29,305 |
| Luu Brendan | Chief Business Officer |
Dec 06 '24 |
Sale |
8.06 |
2,283 |
18,401 |
36,047 |
| Rottinghaus Scott T. | Chief Medical Officer |
Dec 06 '24 |
Sale |
8.06 |
866 |
6,980 |
17,918 |
| Or Yat Sun | Chief Scientific Officer |
Dec 06 '24 |
Sale |
8.06 |
2,591 |
20,883 |
369,109 |
| MELLETT PAUL J | Chief Fin. & Admin Officer |
Dec 06 '24 |
Sale |
8.06 |
2,591 |
20,883 |
91,710 |
| Luly Jay R. | President and CEO |
Dec 06 '24 |
Sale |
8.06 |
5,142 |
41,445 |
801,638 |
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):